Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease.

After decades of research and clinical trials there is still no cure for Alzheimer's disease (AD). While impaired clearance of amyloid beta (Aβ) peptides is considered as one of the major causes of AD, it was recently complemented by a potential role of other toxic amyloidogenic species. Insulin-degrading enzyme (IDE) is the proteolytic culprit of various β-forming peptides, both extracellular and intracellular. On the basis of demonstrated allosteric activation of IDE against Aβ, it is possible to propose a new strategy for the targeted IDE-based cleansing of different toxic aggregation-prone peptides. Consequently, specific allosteric activation of IDE coupled with state-of-the-art compound delivery and CRISP-Cas9 technique of transgene insertion can be instrumental in the fight against AD and related neurodegenerative maladies.

[1]  C. Östenson,et al.  The Type 2 Diabetes–Associated Gene Ide Is Required for Insulin Secretion and Suppression of α-Synuclein Levels in β-Cells , 2013, Diabetes.

[2]  Igor N. Berezovsky,et al.  AlloSigMA: allosteric signaling and mutation analysis server , 2017, Bioinform..

[3]  Yama Akbari,et al.  Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders , 2005, Neurobiology of Aging.

[4]  A. Camins,et al.  Current Research Therapeutic Strategies for Alzheimer's Disease Treatment , 2016, Neural plasticity.

[5]  P. van Endert,et al.  Multiple functions of insulin-degrading enzyme: a metabolic crosslight? , 2017, Critical reviews in biochemistry and molecular biology.

[6]  K. J. Wolfe,et al.  Amyloid in neurodegenerative diseases: friend or foe? , 2011, Seminars in cell & developmental biology.

[7]  D. Selkoe,et al.  Small-Molecule Activators of Insulin-Degrading Enzyme Discovered through High-Throughput Compound Screening , 2009, PloS one.

[8]  C. Nicholson,et al.  Clearance systems in the brain-implications for Alzheimer disease. , 2015, Nature reviews. Neurology.

[9]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[10]  M. MacCoss,et al.  Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism , 2006 .

[11]  David Eisenberg,et al.  In Brief , 2009, Nature Reviews Neuroscience.

[12]  M. Orłowski,et al.  Substrate and inhibitor studies of thermolysin-like neutral metalloendopeptidase from kidney membrane fractions. Comparison with bacterial thermolysin. , 1986, Biochemistry.

[13]  I. Kavakli,et al.  Structure Based Discovery of Small Molecules to Regulate the Activity of Human Insulin Degrading Enzyme , 2012, PloS one.

[14]  S. Marini,et al.  Insulin-degrading Enzyme (IDE) , 2012, The Journal of Biological Chemistry.

[15]  Wei-Jen Tang,et al.  Structures of human CCL18, CCL3, and CCL4 reveal molecular determinants for quaternary structures and sensitivity to insulin degrading enzyme , 2015, Journal of molecular biology.

[16]  I. Kurochkin.  Insulin-degrading enzyme: embarking on amyloid destruction. , 2001, Trends in biochemical sciences.

[17]  Michael R. Schmidt,et al.  Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils. , 2011, Nature chemical biology.

[18]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[19]  D. Vaux,et al.  Heterologous Amyloid Seeding: Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease , 2007, PloS one.

[20]  L. Morelli,et al.  The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme , 2008, Prion.

[21]  D. Richter,et al.  Atrial natriuretic peptide (ANP) is a high-affinity substrate for rat insulin-degrading enzyme. , 1991, European journal of biochemistry.

[22]  D. Selkoe,et al.  The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. , 2000, Biochemistry.

[23]  A. Delacourte,et al.  Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease , 2002, Neurology.

[24]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[25]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[26]  F. Polticelli,et al.  Multiple allosteric sites are involved in the modulation of insulin‐degrading‐enzyme activity by somatostatin , 2016, The FEBS journal.

[27]  P. Wittung-Stafshede,et al.  Insulin-degrading enzyme is activated by the C-terminus of α-synuclein. , 2015, Biochemical and biophysical research communications.

[28]  L. Hersh,et al.  Mixed Dimers of Insulin-degrading Enzyme Reveal a Cis Activation Mechanism* , 2011, The Journal of Biological Chemistry.

[29]  D. Richter,et al.  The rat insulin‐degrading enzyme , 1993, FEBS letters.

[30]  L. Hersh,et al.  Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral. , 2005, Biochemistry.

[31]  David T. Jones,et al.  Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity , 2013, Neurology.

[32]  R. Koenen,et al.  Polymerization of MIP‐1 chemokine (CCL3 and CCL4) and clearance of MIP‐1 by insulin‐degrading enzyme , 2010, The EMBO journal.

[33]  B. Posner,et al.  Endosomal proteolysis of insulin by an acidic thiol metalloprotease unrelated to insulin degrading enzyme. , 1994, The Journal of biological chemistry.

[34]  E. Sigurdsson,et al.  Plaque-Associated Overexpression of Insulin-Degrading Enzyme in the Cerebral Cortex of Aged Transgenic Tg2576 Mice With Alzheimer Pathology , 2006, Journal of neuropathology and experimental neurology.

[35]  Gaël Chételat,et al.  Alzheimer disease: Aβ-independent processes—rethinking preclinical AD , 2013, Nature Reviews Neurology.

[36]  J. Drijfhout,et al.  Reduced amyloid‐β degradation in early Alzheimer's disease but not in the APPswePS1dE9 and 3xTg‐AD mouse models , 2013, Aging cell.

[37]  K. Jellinger,et al.  PART, a distinct tauopathy, different from classical sporadic Alzheimer disease , 2015, Acta Neuropathologica.

[38]  M. Folstein,et al.  Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis , 2006, Neurobiology of Aging.

[39]  M. Coletta,et al.  Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity. , 2009, Journal of molecular biology.

[40]  Huaxi Xu,et al.  Insulin-degrading enzyme sorting in exosomes: a secretory pathway for a key brain amyloid-beta degrading protease. , 2010, Journal of Alzheimer's disease : JAD.

[41]  M. Kirkitadze,et al.  Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies , 2002, Journal of neuroscience research.

[42]  S. Lipton,et al.  Elevated glucose and oligomeric β-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation , 2016, Nature Communications.

[43]  Wei-Jen Tang,et al.  Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme. , 2010, Journal of molecular biology.

[44]  R. Petersen,et al.  Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Aβ42 levels and risk for Alzheimer disease , 2004, Human mutation.

[45]  Matthew P. Frosch,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. Selkoe,et al.  Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. , 2004, The American journal of pathology.

[47]  L. Hersh,et al.  ATP Effects on Insulin-degrading Enzyme Are Mediated Primarily through Its Triphosphate Moiety* , 2004, Journal of Biological Chemistry.

[48]  S. Marini,et al.  Somatostatin Modulates Insulin-Degrading-Enzyme Metabolism: Implications for the Regulation of Microglia Activity in AD , 2012, PloS one.

[49]  Amedeo Caflisch,et al.  Pathways and intermediates of amyloid fibril formation. , 2007, Journal of molecular biology.

[50]  Wei-Jen Tang,et al.  Structure of Substrate-free Human Insulin-degrading Enzyme (IDE) and Biophysical Analysis of ATP-induced Conformational Switch of IDE* , 2007, Journal of Biological Chemistry.

[51]  M. Coletta,et al.  Proteasome Activity Is Affected by Fluctuations in Insulin-Degrading Enzyme Distribution , 2015, PloS one.

[52]  L. Hersh,et al.  Anion Activation Site of Insulin-degrading Enzyme* , 2011, The Journal of Biological Chemistry.

[53]  T. Bayer,et al.  Intracellular Accumulation of Amyloid-Beta – A Predictor for Synaptic Dysfunction and Neuron Loss in Alzheimer's Disease , 2010, Front. Ag. Neurosci..

[54]  P. Greengard,et al.  Intraneuronal Aβ42 Accumulation in Human Brain , 2000 .

[55]  B. Bogerts,et al.  Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques , 1999, Neuroscience Letters.

[56]  J. Bonifacino,et al.  Restricted Location of PSEN2/γ-Secretase Determines Substrate Specificity and Generates an Intracellular Aβ Pool , 2016, Cell.

[57]  L. Hersh,et al.  Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation* , 1998, The Journal of Biological Chemistry.

[58]  F. Hamel,et al.  In vitro inhibition of insulin-degrading enzyme by long-chain fatty acids and their coenzyme A thioesters. , 2003, Endocrinology.

[59]  A. Abbott,et al.  Failed Alzheimer’s trial does not kill leading theory of disease , 2016, Nature.

[60]  S. Lindquist,et al.  Amyloid deposits: Protection against toxic protein species? , 2009, Cell cycle.

[61]  M. Leissring.  Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease. , 2006, Current Alzheimer research.

[62]  L. Morelli,et al.  Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease. , 2009, Current pharmaceutical design.

[63]  Sandra E Black,et al.  Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome , 2013, Alzheimer's Research & Therapy.

[64]  G. de Prat-Gay,et al.  Insulin-degrading enzyme degrades amyloid peptides associated with British and Danish familial dementia. , 2005, Biochemical and biophysical research communications.

[65]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[66]  Wei-Jen Tang,et al.  Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme. , 2008, Biochemistry.

[67]  C. Geula,et al.  Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer's disease. , 2015, Brain : a journal of neurology.

[68]  D. Eisenberg,et al.  Neurodegeneration: Taming tangled tau , 2017, Nature.

[69]  I. Kurochkin,et al.  Alzheimer's β‐amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme , 1994, FEBS letters.

[70]  Frank Eisenhaber,et al.  Toward Allosterically Increased Catalytic Activity of Insulin-Degrading Enzyme against Amyloid Peptides. , 2017, Biochemistry.

[71]  H. Soininen,et al.  Insulin-degrading enzyme is genetically associated with Alzheimer’s disease in the Finnish population , 2007, Journal of Medical Genetics.

[72]  J. Troncoso,et al.  Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease , 2010, Neurobiology of Aging.

[73]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[74]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.

[75]  Simon Mitternacht,et al.  SPACER: server for predicting allosteric communication and effects of regulation , 2013, Nucleic Acids Res..

[76]  W. Duckworth,et al.  Degradation of Intraendosomal Insulin by Insulin-Degrading Enzyme Without Acidification , 1991, Diabetes.

[77]  L. Hersh,et al.  Inositol phosphates and phosphoinositides activate insulin-degrading enzyme, while phosphoinositides also mediate binding to endosomes , 2017, Proceedings of the National Academy of Sciences.

[78]  L. Guarente,et al.  Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. , 2004, The Biochemical journal.

[79]  I. Hamley,et al.  Proteolytically Inactive Insulin-Degrading Enzyme Inhibits Amyloid Formation Yielding Non-Neurotoxic Aβ Peptide Aggregates , 2013, PloS one.

[80]  W. Song,et al.  Molecular links between Alzheimer’s disease and diabetes mellitus , 2013, Neuroscience.

[81]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[82]  Khadija Iqbal,et al.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. , 2008, Current medicinal chemistry.

[83]  Igor N. Berezovsky,et al.  Structure-Based Statistical Mechanical Model Accounts for the Causality and Energetics of Allosteric Communication , 2016, PLoS Comput. Biol..

[84]  L. Hersh,et al.  Mutation of Active Site Residues of Insulin-degrading Enzyme Alters Allosteric Interactions* , 2005, Journal of Biological Chemistry.

[85]  C. Behl.  Amyloid in Alzheimer's Disease: Guilty Beyond Reasonable Doubt? , 2017, Trends in pharmacological sciences.

[86]  Shohei Koide,et al.  Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme , 2013, Proceedings of the National Academy of Sciences.

[87]  Amedeo Caflisch,et al.  Interpreting the aggregation kinetics of amyloid peptides. , 2006, Journal of molecular biology.

[88]  J. Jia,et al.  Exploration of 16 candidate genes identifies the association of IDE with Alzheimer's disease in Han Chinese , 2012, Neurobiology of Aging.

[89]  K. Blennow,et al.  Ex vivo18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway , 2017, Molecular Neurodegeneration.

[90]  Wei-Jen Tang.  Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus , 2016, Trends in Endocrinology & Metabolism.

[91]  D. Selkoe,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[92]  Yama Akbari,et al.  Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. , 2005, Neurobiology of aging.

[93]  P. Wittung-Stafshede,et al.  Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner , 2015, Scientific Reports.

[94]  L. Hersh,et al.  Identification of the Allosteric Regulatory Site of Insulysin , 2011, PloS one.

[95]  Edward M. Callaway,et al.  In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration , 2016, Nature.

[96]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[97]  E. Malito,et al.  Amyloid β-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin , 2008, Cellular and Molecular Life Sciences.

[98]  L. Hersh,et al.  Substrate Activation of Insulin-degrading Enzyme (Insulysin) , 2003, Journal of Biological Chemistry.

[99]  B. Vissel,et al.  Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease , 2014, Acta neuropathologica communications.

[100]  V. Pankratz,et al.  Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, Aß, and Alzheimer's Disease , 2010, PloS one.

[101]  K. Watanabe,et al.  Cellular localization of insulin-degrading enzyme in rat liver using monoclonal antibodies specific for this enzyme. , 1988, Biochemical and biophysical research communications.

[102]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[103]  B. Winblad,et al.  Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE , 2007, Neurobiology of Aging.

[104]  R. Roth,et al.  Overexpression of insulin degrading enzyme: cellular localization and effects on insulin signaling. , 1997, Biochemical and biophysical research communications.

[105]  P. Greengard,et al.  Intraneuronal Abeta42 accumulation in human brain. , 2000, The American journal of pathology.

[106]  S. Younkin,et al.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.

[107]  G. Belfort,et al.  N-Terminal Hypothesis for Alzheimer's Disease. , 2017, ACS chemical neuroscience.

[108]  H. Tanila,et al.  Increased expression of Aβ degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology , 2008, Neuroscience Letters.

[109]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[110]  D. Selkoe,et al.  Molecular basis for the thiol sensitivity of insulin-degrading enzyme , 2008, Proceedings of the National Academy of Sciences.